Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business UpdatesGlobeNewsWire • 03/05/26
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026GlobeNewsWire • 02/26/26
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common StockGlobeNewsWire • 01/29/26
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common StockGlobeNewsWire • 01/28/26
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly24/7 Wall Street • 01/23/26
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASHZacks Investment Research • 01/06/26
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASHGlobeNewsWire • 01/05/26
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH TranscriptSeeking Alpha • 12/19/25
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH TrialGlobeNewsWire • 12/19/25
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?Zacks Investment Research • 12/11/25
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewsWire • 11/26/25
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should KnowZacks Investment Research • 11/25/25
Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/20/25
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025GlobeNewsWire • 11/11/25
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025GlobeNewsWire • 11/07/25